| Zhou, Jian |
NCT05063071: Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant |
|
|
| Active, not recruiting | 4 | 150 | RoW | Tenofovir Alafenamide 25 MG | Fudan University | HBV, POST LIVER TRANSPLANT | 07/22 | 12/22 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06507436: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
|
|
| Recruiting | 3 | 101 | RoW | Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | 08/25 | 09/25 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04850157: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab, IMRT | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 04/22 | 12/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT05262959: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC |
|
|
| Completed | 2 | 30 | RoW | Donafenib, PD-1, TACE | Shanghai Zhongshan Hospital | Donafenib | 04/24 | 05/24 | | |
NCT06530784: Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 36 | RoW | Cryoablation, PD-1 antibody and bevacizumab | Shanghai Zhongshan Hospital | Carcinoma, Hepatocellular | 12/25 | 05/26 | | |
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies |
|
|
| Recruiting | 2 | 60 | RoW | SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 12/25 | 06/26 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
| Recruiting | 1/2 | 30 | RoW | Toripalimab, Sorafenib | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 10/21 | 12/21 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH |
|
|
| Recruiting | N/A | 190 | RoW | Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations | Xiangya Hospital of Central South University | Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage | 12/24 | 03/25 | | |
NCT06178809: Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 475 | RoW | | Singlera Genomics Inc., Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 04/25 | 12/25 | | |
NCT05200221: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice |
|
|
| Recruiting | N/A | 300 | RoW | | Shanghai Zhongshan Hospital | Donafenib, Hepatocellular Carcinoma | 01/24 | 03/24 | | |
NCT05941286: Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital |
|
|
| Recruiting | N/A | 527 | RoW | CGM system with both glucose predictive alerts and threshold alerts on, CGM system with only glucose threshold alerts on, CGM system with glucose alerts off | Shanghai 6th People's Hospital | Diabetes Mellitus | 08/25 | 09/25 | | |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
NCT06591286: Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control |
|
|
| Recruiting | N/A | 150 | RoW | RT-CGM, SMBG | Shanghai 6th People's Hospital | Diabetes Mellitus, Type 2 | 03/26 | 09/27 | | |
NCT06662630: Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients |
|
|
| Recruiting | N/A | 30 | RoW | High-Frequency Oscillatory Ventilation | Shanghai Zhongshan Hospital | Atelectasis, Acute Respiratory Distress Syndrome, VAP - Ventilator Associated Pneumonia | 10/25 | 10/26 | | |
NCT05087459: Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 141 | RoW | Avatrombopag, Doptelet | Shanghai Zhongshan Hospital | Thrombocytopenia | 06/22 | 07/22 | | |
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers |
|
|
| Completed | N/A | 2430 | RoW | | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc. | Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 06/23 | 07/23 | | |
NCT05707585: Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage |
|
|
| Recruiting | N/A | 2064 | RoW | Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH) | The Second Affiliated Hospital of Dalian Medical University, Fudan University, Zongda Hospital affiliated to Southeast University, West China Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shengjing Hospital, The First Affiliated Hospital of Guangzhou Medical University, Lisen Imprinting Diagnostics, Inc. | Lung Cancer | 01/24 | 07/24 | | |
| Hu, Bo |
NCT05585151: High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study |
|
|
| Recruiting | 4 | 200 | RoW | Evolocumab 140 MG/ML, Intensive statin treatment | Wuhan Union Hospital, China | Cerebral Atherosclerosis | 04/24 | 10/24 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
SPAIR-2, NCT05159947: SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial |
|
|
| Recruiting | 3 | 1112 | RoW | SPT-07A injection, placebo | Wuhan Union Hospital, China, Suzhou Huyun New Drug Research and Development Co., Ltd, Shanghai Canming Pharmaceutical Technology Co., Ltd, Beijing Haijinge Pharmaceutical Technology Co., Ltd, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Xiang Yang NO.1 People's Hospital, Xiangyang Central Hospital, Wuhan NO. 4 hospital, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Central Hospital, Yan'an University Xianyang hospital Co., Ltd, Hengshui People's Hospital, Inner Mongolia Baogang Hospital, Daqing oilfield general hospital, The Fourth Affiliated Hospital of Harbin Medical University, The First Hospital of Jilin University, Meihekou Central Hospital, Jiangsu Taizhou People's Hospital, Tianjin People's Hospital, Taizhou Hospital, Zhejiang Taizhou hospital, The First Affiliated Hospital of Nanhua University, Affiliated hospital of jining medical college, Zhongshan Hospital Xiamen University, Neijiang Second People's Hospital, Tancheng first people's Hospital, The Affiliated Hospital of Qingdao University, Taian Central Hospital, Weihai Municipal Hospital, Nanyang nanshai hospital, Dezhou People's Hospital, The First Affiliated Hospital of Nanyang Medical College, Deyang People's Hospital, Yantai Yuhuangding Hospital, Qingdao Central Hospital, Fukuang General Hospital of Liaoning health industry group, Xi'an Gaoxin Hospital, Affiliated Hospital of Jiaxing University, Fujian Zhangzhou hospital, The Affiliated Hospital of Inner Mongolia Medical University, Daqing people's Hospital, Hainan People's Hospital, Qujing first people's Hospital, The Third Affiliated Hospital of Qiqihar Medical College, The First Affiliated Hospital of Hebei North University, Linfen Central Hospital, Xuancheng people's hospital, The First Affiliated Hospital of Shihezi University Medical College, Guangzhou Red Cross Hospital, People's Hospital of Wuhan University, Wuhan Central Hospital, Jingzhou Central Hospital, Huanggang Central Hospital, Sinopharm Dongfeng General Hospital, Changjiang Shipping General Hospital, Yichang Central People's Hospital, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangtan Central Hospital | Stroke, Acute | 01/24 | 01/24 | | |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT05359601: Infusion Set Replacement Intervals for Critically Ill Patients |
|
|
| Recruiting | N/A | 1240 | RoW | Infusion set replacement intervals | Zhongnan Hospital | Critical Illness | 12/25 | 06/26 | | |
| Not yet recruiting | N/A | 300 | NA | smartphone related behaviors | Tang-Du Hospital | Social Media, Mental Health Disorder, Brain Imaging | 10/23 | 06/24 | | |
| Recruiting | N/A | 30 | RoW | Drug screen with PDO/PDO-TIL/PDOTS | Shanghai Zhongshan Hospital | Liver Cancer, Metastatic Liver Cancer | 06/26 | 06/26 | | |
| Zhang, Xiaoping |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 110 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Bladder Cancer | 12/22 | 12/23 | | |
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer |
|
|
| Recruiting | 2 | 115 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Bladder Urothelial Cancer | 12/24 | 06/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors |
|
|
| Not yet recruiting | 1 | 87 | RoW | BPI-452080 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | 03/25 | 10/25 | | |
NCT05812482: Treatment of Urethral Stricture With Urethral Drug Ball |
|
|
| Recruiting | N/A | 150 | RoW | Drug balloon dilatation, Direct vision internal urethrotomy (DVIU) | Lepu Medical Technology (Beijing) Co., Ltd. | Urethral Stricture Less Than 2 cm | 10/24 | 02/25 | | |
NCT05881642: Robot-assisted Function-sparing Cystectomy Followed by Modified Orthotopic Ileal Neobladder |
|
|
| Recruiting | N/A | 20 | RoW | Prostate and seminal-sparing Cystectomy, Conventional Radical Cystoprostatectomy | Wuhan Union Hospital, China | Negative Surgical Margins | 11/25 | 01/26 | | |
| Liu, Lei |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | 3 | 510 | RoW | AK117 in combination with AK112, Placebo in combination with Pembrolizumab | Akeso | Head and Neck Squamous Cell Carcinoma | 01/27 | 10/27 | | |
NCT05076786: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Chidamide, Epidaza, Etoposide + Cisplatin/Carboplatin, EP/EC regimen | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Carcinoma | 10/22 | 10/24 | | |
NCT05113355: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm |
|
|
| Recruiting | 2 | 23 | RoW | Chidamide, Epidaza, Sintilimab, Tyvyt | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm | 11/22 | 11/24 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
AK112-IIT-C-W-0001, NCT06444009: A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Ivonescimab combined with TP, ITP, Cadonilimab combined with TP, CTP, Penpulimab combined with TP, PTP | Lei Liu | Head and Neck Squamous Cell Carcinoma | 12/25 | 12/27 | | |
| Recruiting | 2 | 50 | RoW | Adebrelimab | Sun Yat-sen University, Nanfang Hospital, Southern Medical University, West China Hospital, The First Affiliated Hospital of Xiamen University | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 05/28 | 05/28 | | |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 06/25 | 08/25 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT05042908: Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies |
|
|
| Completed | 1 | 18 | RoW | LBL-003 Injection, LBL-003 | Nanjing Leads Biolabs Co.,Ltd, Henan Cancer Hospital, Hunan Cancer Hospital, Shandong Cancer Hospital and Institute | Advanced Malignant Tumor | 04/23 | 04/23 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
| Completed | N/A | 4991 | NA | TACE | Tang-Du Hospital, Air Force Military Medical University, China, Army Medical University, The First Affiliated Hospital of Shanxi Medical University, Sun Yat-sen University, Shaanxi Provincial People's Hospital, Xijing Hospital, Health Science Center of Xi'an Jiaotong University | HCC, Transarterial Chemoembolization, Resection | 01/21 | 10/21 | | |
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101) |
|
|
| Completed | N/A | 1000 | RoW | | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University | COVID-19, Liver Disease, Vaccine Reaction | 01/22 | 05/22 | | |
NCT06346821: Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data |
|
|
| Completed | N/A | 181 | RoW | Optune® (Tumor Treating Fields) | Sichuan University | Glioblastoma Multiforme | 04/24 | 04/24 | | |
TIPS, NCT06196723: Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites |
|
|
| Completed | N/A | 462 | RoW | transjugular intrahepatic portal shunt | Tang-Du Hospital | Refractory Ascites | 02/24 | 02/24 | | |
NCT05976516: CXCL2/CXCL8 Promote Intervertebral Disc Degeneration |
|
|
| Recruiting | N/A | 40 | RoW | CXCL2/CXCL8 | Zhongda Hospital | Cytokine, Intervertebral Disc, Degenerative | 03/24 | 03/24 | | |
NCT06410716: Comparing Valve-regulated Pleural Drainage to Traditional Closed Chest Tube Drainage |
|
|
| Recruiting | N/A | 100 | RoW | Valve-regulated pleural drainage system | Peking Union Medical College Hospital, Ningbo Xinyue Medical Technology Co., LTD | Lung Cancer | 10/24 | 04/25 | | |
NCT06662071: A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology |
|
|
| Recruiting | N/A | 293 | RoW | Organoid culture | Qilu Hospital of Shandong University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Hospital, The Third Shandong Provincial Hospital, Taian City Central Hospital, Weifang People's Hospital, Binzhou Medical University, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Liaocheng People's Hospital, Linyi People's Hospital, Yantai Yuhuangding Hospital, Zibo Central Hospital, Dezhou People's Hospital, The Affiliated Hospital of Jining Medical University and Zaozhuang City, Qilu Hospital of Shandong University (Qingdao) | Bladder Cancer | 09/28 | 09/28 | | |
NCT04662918: Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding |
|
|
| Recruiting | N/A | 3000 | Europe, US, RoW | | Xingshun Qi | GastroIntestinal Bleeding | 12/24 | 12/24 | | |
| Recruiting | N/A | 102 | US | Orientation and Mobility Training with VR-IOMSs, Orientation and Mobility Training with COMS, No Orientation and Mobility Training | University of Alabama at Birmingham | Low Vision, Both Eyes | 03/25 | 06/25 | | |
RECOGNIZE-I, NCT05884008: Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I |
|
|
| Recruiting | N/A | 300 | RoW | | Ruijin Hospital | Coronary Artery Disease | 06/25 | 12/25 | | |
| Recruiting | N/A | 2000 | RoW | | Ruijin Hospital | Coronary Artery Disease | 09/25 | 12/25 | | |
| Recruiting | N/A | 147 | US | STEGA-MRI | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Peripheral Nerve Injury Upper Limb, Healthy | 12/25 | 12/25 | | |
| Recruiting | N/A | 60 | US | Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI), DBSI MRI | Washington University School of Medicine, National Cancer Institute (NCI) | Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas | 12/32 | 12/32 | | |
NCT04953533: Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout |
|
|
| Recruiting | N/A | 800 | RoW | no intervention | Second Affiliated Hospital, School of Medicine, Zhejiang University | Gout, Hyperuricemia, Gut Microbiota, Uric Acid, Genetic Loci, Single Nucleotide Polymorphism, Feces | 01/23 | 12/23 | | |
| Zhang, Tao |
NCT05175001: Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Thoracic Paravertebral Nerve Block for Chronic Post-thoracotomy Pain |
|
|
| Recruiting | 4 | 100 | RoW | Diprospan, Compound Betamethasone Injection, Ropivacaine | Affiliated Hospital of Nantong University | Chronic Pain | 06/22 | 01/23 | | |
PIONEER, NCT05029453: Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy |
|
|
| Not yet recruiting | 4 | 60 | RoW | Apatinib | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, Randomized Controlled Study | 12/22 | 03/23 | | |
NCT05598177: Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass |
|
|
| Completed | 4 | 64 | RoW | dexmedetomidine, Placebo | Affiliated Hospital of Nantong University | Ischemia-Reperfusion Injury | 05/23 | 12/23 | | |
NCT05922605: Analgesic Effects of Caudal S-ketamine for Supplementation of Ropivacaine Caudal Analgesia in Children With Hypospadias |
|
|
| Recruiting | 4 | 44 | RoW | S-ketamine & Ropivacaine, Ropivacaine | Tao Zhang | Postoperative Analgesia, S-ketamine, Pediatrics, Caudal Block, Hypospadias | 04/25 | 05/25 | | |
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 231 | RoW | Short course radiotherapy sequential camrelizumab and chemotherapy | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Rectal Cancer | 03/23 | 03/26 | | |
NCT03399253: Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor |
|
|
| Recruiting | 3 | 120 | RoW | surgery, chemotherapy, XELOX | Sun Yat-sen University | Gastric Cancer | 11/22 | 12/25 | | |
NCT03399110: XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) |
|
|
| Active, not recruiting | 3 | 1032 | RoW | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | Fudan University | Gastric Cancer | 08/26 | 08/26 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases |
|
|
| Recruiting | 3 | 308 | RoW | mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab | Fudan University | Colorectal Carcinoma, Liver Metastases | 03/24 | 03/26 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT06753890: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) |
|
|
| Not yet recruiting | 3 | 520 | RoW | Changkang granules, Changkang Granules placebo | Tasly Pharmaceutical Group Co., Ltd | Diarrhea-predominant Irritable Boewl Syndrome | 11/26 | 12/26 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NCT03135652: Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation |
|
|
| Withdrawn | 2 | 120 | RoW | adjuvant SBRT, radiotherapy, Chemotherapy, neoadjuvant chemotherapy and adjuvant chemotherapy | Wuhan Union Hospital, China | Radiotherapy, Colorectal Cancer, Liver Metastases | 06/21 | 06/23 | | |
MCRC-LC1, NCT03142282: Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 200 | RoW | maintenance chemotherapy, Consolidative Radiotherapy | Wuhan Union Hospital, China | Metastatic Colorectal Cancer, Radiotherapy | 08/21 | 08/24 | | |
NCT04563975: Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Toripalimab, JS001, Docetaxel, Taxotere, nab-paclitaxel, AI YUE | Tao Zhang | Gastric Cancer Stage IV | 12/22 | 05/23 | | |
NCT05387681: Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric |
|
|
| Not yet recruiting | 2 | 35 | NA | Envafolimab, Endostatin | Wuhan Union Hospital, China | Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy | 07/23 | 12/25 | | |
NCT05202236: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy |
|
|
| Recruiting | 2 | 20 | RoW | pemigatinib | Wuhan Union Hospital, China | Gastric and Colorectal Cancer | 10/23 | 10/24 | | |
UNION PRECISION-I, NCT06234007: Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study |
|
|
| Recruiting | 2 | 45 | RoW | Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine | Wuhan Union Hospital, China, Renmin Hospital of Wuhan University | Locally Advanced Rectal Cancer | 12/24 | 12/27 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06487429: Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab | Wuhan Union Hospital, China, RemeGen Co., Ltd. | Gastric Cancer | 05/26 | 05/28 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
